GPP
NGNE icon

Great Point Partners’s Neurogene NGNE Stock Holding History

Great Point Partners’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.1M Buy
500,000
+150,000
+43% +$2.91M 2.32% 16
2025
Q4 		$7.21M Sell
350,000
-96,814
-22% -$2.41M 2.34% 17
2025
Q3 		$7.74M Sell
446,814
-39,045
-8% -$784K 3.19% 13
2025
Q2 		$7.26M Buy
485,859
+14,895
+3% +$234K 4.72% 6
2025
Q1 		$5.51M Buy
470,964
+28,203
+6% +$490K 2.92% 15
2024
Q4 		$10.1M Sell
442,761
-561,530
-56% -$20.9M 4.77% 8
2024
Q3 		$42.1M Hold
1,004,291
– – 12.4% 1
2024
Q2 		$36.5M Hold
1,004,291
– – 7% 2
2024
Q1 		$51.1M Buy
1,004,291
+10,062
+1% +$336K 7.97% 1
2023
Q4 		$19.3M Buy
+994,229
New +$14.2M 3.28% 14
2020
Q3 		– Sell
-703
Closed -$233K – 39
2020
Q2 		$233K Sell
703
-1,314
-65% -$343K 0.02% 36
2020
Q1 		$459K Buy
+2,017
New +$415K 0.05% 36
2015
Q4 		– Sell
-5,000
Closed -$1.41M – 26
2015
Q3 		$1.41M Buy
+5,000
New +$1.15M 0.56% 29

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Great Point Partners's NGNE Position: Q1 2026 in Review

Great Point Partners increased its Neurogene (NGNE) stake by 43% in Q1 2026, buying an estimated $2.91M and bringing the position to 500,000 shares worth $10.1M. The position accounts for 2.32% of the portfolio, ranked #16.

Great Point Partners first reported a position in NGNE in Q3 2015 and has held it in 13 quarters since. The position peaked at $51.1M in Q1 2024. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Great Point Partners held 500,000 shares of Neurogene worth $10.1M as of Q1 2026.
  • Great Point Partners bought 150,000 Neurogene shares in Q1 2026, an estimated $2.91M.
  • Neurogene made up 2.32% of Great Point Partners's portfolio in Q1 2026, its #16 holding.
  • Great Point Partners first reported a position in Neurogene in Q3 2015 and has held it in 13 quarters since.
  • Great Point Partners's Neurogene position peaked at $51.1M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Great Point Partners's 13F filing for Q1 2026, filed 15 May 2026.